Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931146 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL826755 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7911543 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL826329 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL2702010 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL16487196 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL345583 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL22276615 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL22276602 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL8002115 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563703-B | Compound for inducing PARP-1 degradation based on CRBN ligand, preparation method and application | 浙江省医学科学院 | 2021-04-09 | — | — | CN | claimed |
| CN-110563703-A | compound for inducing PARP-1 degradation based on CRBN ligand, preparation method and application | 浙江省医学科学院 | 2019-12-13 | — | — | CN | claimed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250243159-A9 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12331061-B2 | Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-06-17 | — | — | US | disclosed |
| CN-120118066-A | Novel cationic lipid compounds, preparation method, composition and application thereof | 杭州睿导基因科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-1190389-A | Novel farnesyl transferase inhibitors, process for their preparation and pharmaceutical compositions containing them | RHONE POULENC RORER SA (FR) | 1998-08-12 | — | — | CN | disclosed |
| US-5676831-A | ANXIOLYTIC AGENTS, ANTICONVULSANTS | RHONE-POULEC RORER S.A. (FR) | 1997-10-14 | — | — | US | disclosed |
| US-5663296-A | OLIGOPEPTIDES AS HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS AND BRAIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| US-5599936-A | HYDRATION OF RACEMIC MIXTURE | RHONE-POUELNC RORER S.A. (FR) | 1997-02-04 | — | — | US | disclosed |
| WO-1996040273-A2 | CONJUGATES OF FERRITES AND OLIGONUCLEOTIDES, WHICH BOND SPECIFICALLY TO CERTAIN TARGET STRUCTURES | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-12-19 | — | — | WO | disclosed |
| US-5534499-A | Lipophilic drug derivatives for use in liposomes | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-07-09 | — | — | US | disclosed |
| US-5494915-A | RACEMIC MIXTURES AS MUSCLE RELAXANTS, ANXIOLYTIC, ANTIEPILEPTIC OR ANTICONVULSIVE AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-27 | — | — | US | disclosed |
| US-5405766-A | Immobilization of biologically active protein on a support with a 7-18 carbon spacer and a bifunctional phospholipid | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 1995-04-11 | — | — | US | disclosed |
| WO-1994028012-A1 | HYDROXAMATE INHIBITORS OF ENDOTHELIN CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243159-A9 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | MUC1, APOB, PLTP | TDP1 1483/4885MEN1 923/4885GAA 145/4885 |
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | TTR, CRYAA, BCL6 | TDP1 1226/4885MEN1 2701/4885GAA 26/4885 |
| US-12331061-B2 | Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof | AR, ESRRA, ESR1 | TDP1 2668/4885MEN1 1721/4885GAA 296/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | TDP1 3232/4885MEN1 1998/4885GAA 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.